

## REMARKS

### Interview Summary

A telephonic interview was held between the undersigned and Examiner Cheu on January 11, 2007. The Restriction Requirement and election of Group IV (Claims 16-29) and marker Alpha-1-antichymotrypsin precursor (ACT) having GenBank accession number P01011 and GenInfo Identifier sequence identification number 112874 (RA Marker #7) were discussed. In the interest of expediting prosecution, the following six markers were selected for examination:

| RA Marker # | Protein Description   |
|-------------|---|
| 83          | hypothetical protein DKFZp434P1818.1 - human (fragment)       |
| 92          | similar to KIAA1902 protein [Homo sapiens]                    |
| 9           | leucine-rich alpha-2-glycoprotein [Homo sapiens]              |
| 57          | gelsolin (amyloidosis, Finnish type); Gelsolin [Homo sapiens] |
| 62          | lumican [Homo sapiens]  |

### Preliminary Amendment

This Preliminary Amendment updates the priority information and makes amendments to the claims solely for the purpose of expediting prosecution. The amendments reflect the subject matter discussed in the telephonic interview of January 11, 2007. Applicant reserves the right to pursue cancelled subject matter in a continuing application.

### Closing Remarks

If it would be helpful to obtain favorable consideration of this case, the Examiner is encouraged to call and discuss this case with the undersigned. No fee is believed due with this submission; however, the undersigned hereby authorizes the charge of any fees created by the

filing of this document or any deficiency of fees submitted herewith to be charged to deposit account No. 19-1970.

Respectfully submitted,

SHERIDAN ROSS P.C.

By: /Darla G. Yoerg/

Darla G. Yoerg

Registration No. 48,053

1560 Broadway, Suite 1200

Denver, Colorado 80202-5141

(303) 863-9700

Date: January 16, 2007